share_log

Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35

Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35

Leerink Partners将Myriad Genetics上调至跑赢大盘,将目标股价上调至35美元
Benzinga ·  05/08 13:54

Leerink Partners analyst Puneet Souda upgrades Myriad Genetics (NASDAQ:MYGN) from Market Perform to Outperform and raises the price target from $25 to $35.

Leerink Partners分析师Puneet Souda将Myriad Genetics(纳斯达克股票代码:MYGN)从市场表现上调至跑赢大盘,并将目标股价从25美元上调至35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发